Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 May, 2018 09:43 IST
Piramal Enterprises concludes acquisition of drug portfolio from Mallinckrodt
Source: IRIS | 20 Mar, 2017, 10.28AM
Comments  |  Post Comment

Piramal Enterprises, one of India's largest diversified companies with a presence in pharmaceutical, financial services, announced that its wholly owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (Mallinckrodt).

As indicated in the Press Release dated January 30, 2017, the acquisition was for a cash consideration of USD 171 million and up to an additional USD 32 million payable depending on financial performance of the acquired assets over the next three years.

The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen has also been approved for launch in eight European markets.

Gablofen is the only intrathecal baclofen drug available in vials and pre-filled syringes, which are preferred by users over the competing products available in ampoules. The pain management drugs under development are also for intrathecal administration. In the twelve months ending September 30, 2016, the acquired portfolio generated revenues of USD 44.6 million.

Shares of the company gained Rs 9.25, or 0.5%, to trade at Rs 1,871.90. The total volume of shares traded was 217 at the BSE (10.17 a.m., Monday).



Piramal Enterprises Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Wipro Gallagher Solutions launches NetOxygen Saas for Loan Origination - 22-May-2018 09:41
Glenmark submits Ryaltris NDA application to USFDA - 22-May-2018 09:38
L&T Construction wins orders worth Rs 40.33 bn - 22-May-2018 09:33
Ind-Ra downgrades Reliance Infra and its NCDs to 'BBB+' - 21-May-2018 15:31
UltraTech to acquire demerged cement division of Century Textiles - 21-May-2018 10:38
Thermax to acquire stake of Babcock & Wilcox in JV - 21-May-2018 10:29
L&T Hydrocarbon wins two contracts for fertilizer plants - 21-May-2018 10:24
Glenmark Pharma gets nod for Colesevelam HCl tablets - 21-May-2018 10:00
Ashok Leyland quarterly net surges 40% - 18-May-2018 16:38
Bank of Baroda enters into MoU with CCRL - 18-May-2018 16:31
Strides Shasun turns to loss in Jan-Mar quarter - 18-May-2018 15:32
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer